• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Improving the use of research evidence in guideline development: 8. Synthesis and presentation of evidence.改善研究证据在指南制定中的应用:8. 证据的综合与呈现。
Health Res Policy Syst. 2006 Dec 5;4:20. doi: 10.1186/1478-4505-4-20.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Improving the use of research evidence in guideline development: 16. Evaluation.提高研究证据在指南制定中的应用:16. 评估。
Health Res Policy Syst. 2006 Dec 8;4:28. doi: 10.1186/1478-4505-4-28.
4
Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement.提高研究证据在指南制定中的应用:10. 整合价值观与消费者参与。
Health Res Policy Syst. 2006 Dec 5;4:22. doi: 10.1186/1478-4505-4-22.
5
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
6
Improving the use of research evidence in guideline development: 2. Priority setting.改善研究证据在指南制定中的应用:2. 确定优先事项。
Health Res Policy Syst. 2006 Nov 29;4:14. doi: 10.1186/1478-4505-4-14.
7
Improving the use of research evidence in guideline development: 12. Incorporating considerations of equity.在指南制定中提高研究证据的应用:12. 纳入公平性考量
Health Res Policy Syst. 2006 Dec 5;4:24. doi: 10.1186/1478-4505-4-24.
8
Improving the use of research evidence in guideline development: 13. Applicability, transferability and adaptation.提高研究证据在指南制定中的应用:13. 适用性、可转移性与适应性。
Health Res Policy Syst. 2006 Dec 8;4:25. doi: 10.1186/1478-4505-4-25.
9
Improving the use of research evidence in guideline development: 14. Reporting guidelines.提高研究证据在指南制定中的应用:14. 报告指南。
Health Res Policy Syst. 2006 Dec 8;4:26. doi: 10.1186/1478-4505-4-26.
10
Improving the use of research evidence in guideline development: 3. Group composition and consultation process.改善研究证据在指南制定中的应用:3. 小组构成与咨询过程。
Health Res Policy Syst. 2006 Nov 29;4:15. doi: 10.1186/1478-4505-4-15.

引用本文的文献

1
Guidance for engagement in health guideline development: A scoping review.参与健康指南制定的指导意见:一项范围综述
Campbell Syst Rev. 2024 Nov 25;20(4):e70006. doi: 10.1002/cl2.70006. eCollection 2024 Dec.
2
Challenges in the Implementation of EU Risk Minimisation Measures for Medicinal Products in Clinical Practice Guidelines: Mixed Methods Multi-Case Study.欧盟药品风险最小化措施在临床实践指南中的实施挑战:混合方法多案例研究
Drug Saf. 2025 Feb;48(2):161-177. doi: 10.1007/s40264-024-01487-5. Epub 2024 Nov 21.
3
Validity of data extraction in acupuncture meta-analysis: a reproducibility study protocol.针刺荟萃分析中数据提取的有效性:一项可重复性研究方案。
BMJ Open. 2024 Nov 7;14(11):e088736. doi: 10.1136/bmjopen-2024-088736.
4
Development of quality assessment tool for systematic reviews and meta-analyses of real-world studies: a Delphi consensus survey.真实世界研究系统评价和荟萃分析质量评估工具的开发:德尔菲共识调查。
Rheumatol Int. 2024 Jul;44(7):1275-1281. doi: 10.1007/s00296-024-05595-4. Epub 2024 Apr 29.
5
Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts.关于如何在监管、卫生技术评估和临床指南制定之间架起桥梁的观点:一项与欧洲专家进行的定性焦点小组研究。
BMJ Open. 2023 Aug 28;13(8):e072309. doi: 10.1136/bmjopen-2023-072309.
6
PROTOCOL: Guidance for stakeholder engagement in guideline development: A systematic review.方案:利益相关者参与指南制定的指导意见:一项系统评价
Campbell Syst Rev. 2022 May 11;18(2):e1242. doi: 10.1002/cl2.1242. eCollection 2022 Jun.
7
Usefulness of Cochrane Reviews in Clinical Guideline Development-A Survey of 585 Recommendations.Cochrane 综述在临床指南制定中的作用——对 585 项推荐意见的调查。
Int J Environ Res Public Health. 2022 Jan 7;19(2):685. doi: 10.3390/ijerph19020685.
8
Overview of the Effect of Complementary Medicine on Treating or Mitigating the Risk of Endometriosis.补充医学治疗或减轻子宫内膜异位症风险的效果概述。
Rev Bras Ginecol Obstet. 2021 Dec;43(12):919-925. doi: 10.1055/s-0041-1735156. Epub 2021 Dec 21.
9
Evaluating the Quality of Systematic Reviews and Meta-Analyses About Breast Augmentation Using AMSTAR.使用AMSTAR评估关于隆胸的系统评价和Meta分析的质量。
Aesthet Surg J Open Forum. 2021 May 22;3(3):ojab020. doi: 10.1093/asjof/ojab020. eCollection 2021 Sep.
10
Quality assessment tools used in systematic reviews of in vitro studies: A systematic review.系统评价中用于体外研究的质量评估工具:系统评价。
BMC Med Res Methodol. 2021 May 8;21(1):101. doi: 10.1186/s12874-021-01295-w.

本文引用的文献

1
Improving the use of research evidence in guideline development: 14. Reporting guidelines.提高研究证据在指南制定中的应用:14. 报告指南。
Health Res Policy Syst. 2006 Dec 8;4:26. doi: 10.1186/1478-4505-4-26.
2
Improving the use of research evidence in guideline development: 11. Incorporating considerations of cost-effectiveness, affordability and resource implications.提高研究证据在指南制定中的应用:11. 纳入成本效益、可负担性及资源影响方面的考量
Health Res Policy Syst. 2006 Dec 5;4:23. doi: 10.1186/1478-4505-4-23.
3
Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement.提高研究证据在指南制定中的应用:10. 整合价值观与消费者参与。
Health Res Policy Syst. 2006 Dec 5;4:22. doi: 10.1186/1478-4505-4-22.
4
Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations.提高研究证据在指南制定中的应用:9. 证据分级与推荐意见
Health Res Policy Syst. 2006 Dec 5;4:21. doi: 10.1186/1478-4505-4-21.
5
Improving the use of research evidence in guideline development: 7. Deciding what evidence to include.改善指南制定过程中研究证据的应用:7. 决定纳入哪些证据。
Health Res Policy Syst. 2006 Dec 1;4:19. doi: 10.1186/1478-4505-4-19.
6
Improving the use of research evidence in guideline development: 5. Group processes.改善研究证据在指南制定中的应用:5. 小组流程。
Health Res Policy Syst. 2006 Dec 1;4:17. doi: 10.1186/1478-4505-4-17.
7
Improving the use of research evidence in guideline development: 2. Priority setting.改善研究证据在指南制定中的应用:2. 确定优先事项。
Health Res Policy Syst. 2006 Nov 29;4:14. doi: 10.1186/1478-4505-4-14.
8
Improving the use of research evidence in guideline development: introduction.提高研究证据在指南制定中的应用:引言
Health Res Policy Syst. 2006 Nov 20;4:12. doi: 10.1186/1478-4505-4-12.
9
Investing in updating: how do conclusions change when Cochrane systematic reviews are updated?投资于更新:当Cochrane系统评价更新时结论如何变化?
BMC Med Res Methodol. 2005 Oct 14;5:33. doi: 10.1186/1471-2288-5-33.
10
Is evidence-based medicine relevant to the developing world?: Systematic reviews have yet to achieve their potential as a resource for practitioners in developing countries.循证医学与发展中国家相关吗?:系统评价尚未发挥其作为发展中国家从业者资源的潜力。
Evid Based Complement Alternat Med. 2005 Sep;2(3):321-4. doi: 10.1093/ecam/neh114.

改善研究证据在指南制定中的应用:8. 证据的综合与呈现。

Improving the use of research evidence in guideline development: 8. Synthesis and presentation of evidence.

作者信息

Oxman Andrew D, Schünemann Holger J, Fretheim Atle

机构信息

Norwegian Knowledge Centre for the Health Services, P,O, Box 7004, St, Olavs plass, N-0130 Oslo, Norway.

出版信息

Health Res Policy Syst. 2006 Dec 5;4:20. doi: 10.1186/1478-4505-4-20.

DOI:10.1186/1478-4505-4-20
PMID:17147809
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1702353/
Abstract

BACKGROUND

The World Health Organization (WHO), like many other organisations around the world, has recognised the need to use more rigorous processes to ensure that health care recommendations are informed by the best available research evidence. This is the eighth of a series of 16 reviews that have been prepared as background for advice from the WHO Advisory Committee on Health Research to WHO on how to achieve this.

OBJECTIVES

We reviewed the literature on the synthesis and presentation of research evidence, focusing on four key questions.

METHODS

We searched PubMed and three databases of methodological studies for existing systematic reviews and relevant methodological research. We did not conduct systematic reviews ourselves. Our conclusions are based on the available evidence, consideration of what WHO and other organisations are doing and logical arguments.

KEY QUESTIONS AND ANSWERS

We found two reviews of instruments for critically appraising systematic reviews, several studies of the importance of using extensive searches for reviews and determining when it is important to update reviews, and consensus statements about the reporting of reviews that informed our answers to the following questions. How should existing systematic reviews be critically appraised? Because preparing systematic reviews can take over a year and require capacity and resources, existing reviews should be used when possible and updated, if needed. Standard criteria, such as A MeaSurement Tool to Assess Reviews (AMSTAR), should be used to critically appraise existing systematic reviews, together with an assessment of the relevance of the review to the questions being asked. When and how should WHO undertake or commission new reviews? Consideration should be given to undertaking or commissioning a new review whenever a relevant, up-to-date review of good quality is not available. When time or resources are limited it may be necessary to undertake rapid assessments. The methods that are used to do these assessments should be reported, including important limitations and uncertainties and explicit consideration of the need and urgency of undertaking a full systematic review. Because WHO has limited capacity for undertaking systematic reviews, reviews will often need to be commissioned when a new review is needed. Consideration should be given to establishing collaborating centres to undertake or support this work, similar to what some national organisations have done. How should the findings of systematic reviews be summarised and presented to committees responsible for making recommendations? Concise summaries (evidence tables) of the best available evidence for each important outcome, including benefits, harms and costs, should be presented to the groups responsible for making recommendations. These should include an assessment of the quality of the evidence and a summary of the findings for each outcome. The full systematic reviews, on which the summaries are based, should also be available to both those making recommendations and users of the recommendations. What additional information is needed to inform recommendations and how should this information be synthesised with information about effects and presented to committees? Additional information that is needed to inform recommendations includes factors that might modify the expected effects, need (prevalence, baseline risk or status), values (the relative importance of key outcomes), costs and the availability of resources. Any assumptions that are made about values or other factors that may vary from setting to setting should be made explicit. For global guidelines that are intended to inform decisions in different settings, consideration should be given to using a template to assist the synthesis of information specific to a setting with the global evidence of the effects of the relevant interventions.

摘要

背景

世界卫生组织(WHO)与世界上许多其他组织一样,认识到需要采用更严谨的流程,以确保医疗保健建议以现有最佳研究证据为依据。这是为世界卫生组织健康研究咨询委员会向WHO提供如何实现这一目标的建议所准备的16篇综述系列中的第八篇。

目的

我们回顾了关于研究证据的综合与呈现的文献,重点关注四个关键问题。

方法

我们在PubMed和三个方法学研究数据库中搜索现有的系统综述和相关的方法学研究。我们自己没有进行系统综述。我们的结论基于现有证据、对WHO和其他组织正在开展工作的考量以及逻辑论证。

关键问题与答案

我们发现了两篇关于严格评价系统综述工具的综述、几项关于在综述中进行全面检索以及确定何时更新综述很重要的研究,以及关于综述报告的共识声明,这些为我们回答以下问题提供了依据。应如何严格评价现有的系统综述?由于编写系统综述可能需要一年多时间,且需要能力和资源,因此应尽可能使用现有综述,并在需要时进行更新。应使用标准标准,如评估综述的测量工具(AMSTAR),对现有系统综述进行严格评价,并评估综述与所提问题的相关性。WHO应在何时以及如何开展或委托进行新的综述?每当没有高质量的相关最新综述时,都应考虑开展或委托进行新的综述。当时间或资源有限时,可能有必要进行快速评估。应报告用于这些评估的方法,包括重要的局限性和不确定性,以及对进行全面系统综述的必要性和紧迫性的明确考量。由于WHO开展系统综述的能力有限,因此在需要进行新的综述时,通常需要委托他人进行。应考虑建立合作中心来开展或支持这项工作,类似于一些国家组织所做的那样。应如何总结系统综述的结果并向负责提出建议的委员会进行呈现?应向负责提出建议的小组提供关于每个重要结果(包括益处、危害和成本)的现有最佳证据的简明摘要(证据表)。这些应包括对证据质量的评估以及每个结果的研究结果总结。作为摘要基础的完整系统综述也应提供给提出建议者和建议使用者。为提出建议还需要哪些额外信息,以及应如何将这些信息与效应信息进行综合并呈现给委员会?为提出建议所需的额外信息包括可能改变预期效应的因素、需求(患病率、基线风险或状况)、价值观(关键结果的相对重要性)、成本以及资源的可用性。应对价值观或其他可能因环境而异的因素所做的任何假设进行明确说明。对于旨在为不同环境下的决策提供依据的全球指南,应考虑使用模板来协助将特定于某一环境的信息与相关干预措施效应的全球证据进行综合。